Genera, Healthscope Sign Collaboration Agreement
RTI-plex, as the test is to be known, will be based upon the same AmpaSand diagnostic platform used in Genera’s PapType HPV test, also used in Healthscope’s diagnostic laboratories, said Genera.
The agreement sees Healthscope providing funding to develop RTI-plex to a point where it can be self-validated by Healthscope for use in its own laboratories. Genera will then take the product through Australian and international regulatory approvals and will retain the right to pursue a range of distribution models, including possible out-licensing.
Genera said that RTI-plex will be able to distinguish between a number of different infectious agents present in a clinical specimen. The target organisms will include a range of different influenza types, including the H1N1 strain responsible for the 2009 epidemic, as well as respiratory syncytial virus, an important pathogen in children and adults suffering from bronchial disease, and SARS.
Fernando Careri, chairman of Genera, said: “This is a model that has worked very well for us previously with PapType, and is very much a win-win for both parties. Healthscope gets early access to a new test, providing a competitive edge in the Australian pathology market, while Genera’s costs of bringing a new product to market are offset by Healthscope’ contribution.”
Will this collaboration help the companies to succeed in Australian pathology market?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.